



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 8, 2018 April 5, 2023, August 19, 2024

FASENRA™ (benralizumab)

LENGTH OF AUTHORIZATION: One year

REVIEW CRITERIA:

- Patient **must be ≥ 6 years of age; AND**
- **Must have** diagnosis of severe asthma **and with an eosinophilic phenotype; AND**
- Prescribed **by** or in consultation with an allergist, pulmonologist, or immunologist; **AND**
- Must have a blood eosinophil count of ≥ 150 cells/mcL (documentation **required**); **AND**
- Patient has ongoing symptoms of asthma with a minimum three-month trial of an inhaled corticosteroid plus a long-acting beta 2 agonist (LABA) combination therapy; **AND**
- Fasenra will not be used in combination with other biologics (e.g. Xolair, Remicade, Enbrel, Humira, etc.).

CONTINUATION OF THERAPY:

- Initial approval criteria for therapy has been met at the time of initiation of therapy.
- Fasenra will not be used in combination with other biologics (e.g. Xolair, Remicade, Enbrel, Humira, etc.).
- Dosing is appropriate as per labeling or is supported by compendia.
- Treatment with Fasenra has resulted in clinical improvement as documented in progress notes by:
 - One or more of the following:
 - Decreased utilization of rescue medications; **OR**
 - Decreased frequency of exacerbations (defined as worsening of asthma that requires increase in inhaled corticosteroid dose or treatment with systemic corticosteroids); **OR**
 - Reduction in reported asthma-related symptoms, such as, but not limited to, wheezing, shortness of breath, coughing, fatigue, sleep disturbance, or asthmatic symptoms upon awakening.
- Continued use of inhaled corticosteroid plus LABA combination while on Fasenra therapy for asthma is documented.
- Patients should periodically be reassessed for the need to continue therapy based on the disease severity and/or the level of asthma control.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 10 mg/0.5 mL and 30 mg/mL single-dose prefilled syringe and 30 mg/mL single-dose autoinjector pen.